A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Postischemic Brain Injury

I. Chen Yu, Ping Chang Kuo, Jui Hung Yen, Hallel C. Paraiso, Eric T. Curfman, Benecia C. Hong-Goka, Robert D. Sweazey, Fen-Lei Chang

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Cerebral ischemia leads to multifaceted injury to the brain. A polytherapeutic drug that can be administered immediately after reperfusion may increase protection to the brain by simultaneously targeting multiple deleterious cascades. This study evaluated efficacy of the combination of three clinically approved drugs: lamotrigine, minocycline, and lovastatin, using two mouse models: global and focal cerebral ischemia induced by transient occlusion of the common carotid arteries or the middle cerebral artery, respectively. In vitro, the combination drug, but not single drug, protected neurons against oxygen-glucose deprivation (OGD)-induced cell death. The combination drug simultaneously targeted cell apoptosis and DNA damage induced by ischemia. Besides acting on neurons, the combination drug suppressed inflammatory processes in microglia and brain endothelial cells induced by ischemia. In a transient global ischemia model, the combination drug, but not single drug, suppressed microglial activation and inflammatory cytokine production, and reduced neuronal damage. In a transient focal ischemia model, the combination drug, but not single drug, attenuated brain infarction, suppressed infiltration of peripheral neutrophils, and reduced neurological deficits following ischemic stroke. In summary, the combination drug confers a broad-spectrum protection against ischemia/reperfusion (I/R) injury and could be a promising approach for early neuroprotection after out-of-hospital cardiac arrest or ischemic stroke.

Original languageEnglish (US)
Pages (from-to)1-18
Number of pages18
JournalTranslational Stroke Research
DOIs
StateAccepted/In press - Jun 17 2017

Fingerprint

Drug Repositioning
Drug Combinations
Brain Injuries
Reperfusion
Ischemia
Pharmaceutical Preparations
Therapeutics
Stroke
Brain Infarction
Out-of-Hospital Cardiac Arrest
Neurons
Lovastatin
Minocycline
Neutrophil Infiltration
Common Carotid Artery
Transient Ischemic Attack
Middle Cerebral Artery
Brain
Microglia
Reperfusion Injury

Keywords

  • Brain infarction
  • Cerebral ischemia
  • Neuroinflammation
  • Neuroprotection

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Cardiology and Cardiovascular Medicine

Cite this

A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Postischemic Brain Injury. / Yu, I. Chen; Kuo, Ping Chang; Yen, Jui Hung; Paraiso, Hallel C.; Curfman, Eric T.; Hong-Goka, Benecia C.; Sweazey, Robert D.; Chang, Fen-Lei.

In: Translational Stroke Research, 17.06.2017, p. 1-18.

Research output: Contribution to journalArticle

Yu, I. Chen ; Kuo, Ping Chang ; Yen, Jui Hung ; Paraiso, Hallel C. ; Curfman, Eric T. ; Hong-Goka, Benecia C. ; Sweazey, Robert D. ; Chang, Fen-Lei. / A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Postischemic Brain Injury. In: Translational Stroke Research. 2017 ; pp. 1-18.
@article{e95450e8b28e48bd8c81b1aadbfde887,
title = "A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Postischemic Brain Injury",
abstract = "Cerebral ischemia leads to multifaceted injury to the brain. A polytherapeutic drug that can be administered immediately after reperfusion may increase protection to the brain by simultaneously targeting multiple deleterious cascades. This study evaluated efficacy of the combination of three clinically approved drugs: lamotrigine, minocycline, and lovastatin, using two mouse models: global and focal cerebral ischemia induced by transient occlusion of the common carotid arteries or the middle cerebral artery, respectively. In vitro, the combination drug, but not single drug, protected neurons against oxygen-glucose deprivation (OGD)-induced cell death. The combination drug simultaneously targeted cell apoptosis and DNA damage induced by ischemia. Besides acting on neurons, the combination drug suppressed inflammatory processes in microglia and brain endothelial cells induced by ischemia. In a transient global ischemia model, the combination drug, but not single drug, suppressed microglial activation and inflammatory cytokine production, and reduced neuronal damage. In a transient focal ischemia model, the combination drug, but not single drug, attenuated brain infarction, suppressed infiltration of peripheral neutrophils, and reduced neurological deficits following ischemic stroke. In summary, the combination drug confers a broad-spectrum protection against ischemia/reperfusion (I/R) injury and could be a promising approach for early neuroprotection after out-of-hospital cardiac arrest or ischemic stroke.",
keywords = "Brain infarction, Cerebral ischemia, Neuroinflammation, Neuroprotection",
author = "Yu, {I. Chen} and Kuo, {Ping Chang} and Yen, {Jui Hung} and Paraiso, {Hallel C.} and Curfman, {Eric T.} and Hong-Goka, {Benecia C.} and Sweazey, {Robert D.} and Fen-Lei Chang",
year = "2017",
month = "6",
day = "17",
doi = "10.1007/s12975-017-0543-5",
language = "English (US)",
pages = "1--18",
journal = "Translational Stroke Research",
issn = "1868-4483",
publisher = "Springer US",

}

TY - JOUR

T1 - A Combination of Three Repurposed Drugs Administered at Reperfusion as a Promising Therapy for Postischemic Brain Injury

AU - Yu, I. Chen

AU - Kuo, Ping Chang

AU - Yen, Jui Hung

AU - Paraiso, Hallel C.

AU - Curfman, Eric T.

AU - Hong-Goka, Benecia C.

AU - Sweazey, Robert D.

AU - Chang, Fen-Lei

PY - 2017/6/17

Y1 - 2017/6/17

N2 - Cerebral ischemia leads to multifaceted injury to the brain. A polytherapeutic drug that can be administered immediately after reperfusion may increase protection to the brain by simultaneously targeting multiple deleterious cascades. This study evaluated efficacy of the combination of three clinically approved drugs: lamotrigine, minocycline, and lovastatin, using two mouse models: global and focal cerebral ischemia induced by transient occlusion of the common carotid arteries or the middle cerebral artery, respectively. In vitro, the combination drug, but not single drug, protected neurons against oxygen-glucose deprivation (OGD)-induced cell death. The combination drug simultaneously targeted cell apoptosis and DNA damage induced by ischemia. Besides acting on neurons, the combination drug suppressed inflammatory processes in microglia and brain endothelial cells induced by ischemia. In a transient global ischemia model, the combination drug, but not single drug, suppressed microglial activation and inflammatory cytokine production, and reduced neuronal damage. In a transient focal ischemia model, the combination drug, but not single drug, attenuated brain infarction, suppressed infiltration of peripheral neutrophils, and reduced neurological deficits following ischemic stroke. In summary, the combination drug confers a broad-spectrum protection against ischemia/reperfusion (I/R) injury and could be a promising approach for early neuroprotection after out-of-hospital cardiac arrest or ischemic stroke.

AB - Cerebral ischemia leads to multifaceted injury to the brain. A polytherapeutic drug that can be administered immediately after reperfusion may increase protection to the brain by simultaneously targeting multiple deleterious cascades. This study evaluated efficacy of the combination of three clinically approved drugs: lamotrigine, minocycline, and lovastatin, using two mouse models: global and focal cerebral ischemia induced by transient occlusion of the common carotid arteries or the middle cerebral artery, respectively. In vitro, the combination drug, but not single drug, protected neurons against oxygen-glucose deprivation (OGD)-induced cell death. The combination drug simultaneously targeted cell apoptosis and DNA damage induced by ischemia. Besides acting on neurons, the combination drug suppressed inflammatory processes in microglia and brain endothelial cells induced by ischemia. In a transient global ischemia model, the combination drug, but not single drug, suppressed microglial activation and inflammatory cytokine production, and reduced neuronal damage. In a transient focal ischemia model, the combination drug, but not single drug, attenuated brain infarction, suppressed infiltration of peripheral neutrophils, and reduced neurological deficits following ischemic stroke. In summary, the combination drug confers a broad-spectrum protection against ischemia/reperfusion (I/R) injury and could be a promising approach for early neuroprotection after out-of-hospital cardiac arrest or ischemic stroke.

KW - Brain infarction

KW - Cerebral ischemia

KW - Neuroinflammation

KW - Neuroprotection

UR - http://www.scopus.com/inward/record.url?scp=85020505204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020505204&partnerID=8YFLogxK

U2 - 10.1007/s12975-017-0543-5

DO - 10.1007/s12975-017-0543-5

M3 - Article

SP - 1

EP - 18

JO - Translational Stroke Research

JF - Translational Stroke Research

SN - 1868-4483

ER -